117 results

Irish drugmaker Elan, which shares sales of the MS drug Tysabri with Biogen, said yesterday that sales of that medicine grew 14 per cent in the quarter to $456 million.

Biogen Idec Inc reported higher-than-expected first quarter profit today, helped by low taxes and sales growth of its injectable multiple scler(...)

Elan executives at a recent egm in the Westin Hotel in Dublin [ FROM LEFT] G.Kelly Martin chief executive, Robert A Ingram, chairman and Liam Daniel, company secretary . Photograph: Cyril Byrne/Irish Times

The board of drugmaker Elan has unanimously rejected a formal bid from Royalty Pharma , saying the US investment firm's offer of $11.25 a share(...)

Elan chairman Robert A Ingram at the company’s egm in Dublin last week.  The results of the Royalty Pharma tender offer suggest shareholders believe Elan can be rebuilt through acquisitions or that Royalty will come back with a higher bid. Photograph: Cyril Byrne

Elan shareholders gave the Irish drugmaker a boost in its hopes of fending off a $7.3 billion bid from Royalty Pharma when they ignored a plea (...)

Shareholders approved Elan’s  $1 billion share buyback this morning. Photograph: Alan Betson / THE IRISH TIMES

Irish drugmaker Elan got strong approval from shareholders for a $1 billion (€766,000) share buyback as it seeks to keep them on side and stave(...)

Richard Pops, chief executive  of Alkermes pictured in their Dublin offices in May 2012 following the EDT deal. Photo: Aidan Crawley

Alkermes, the US company that acquired Elan’s drug manufacturing business in Athlone, announced today that it will cut almost a third of the wo(...)

Robert Ingram, chairman of Elan with Kelly Martin, CEO. Photograph: David Sleator

Royalty Pharma must make an offer for Elan by May 10th or announce it will not proceed, the Irish Takeover Panel said yesterday. The deci(...)

Irish biopharma group Elan has closed a deal to transfer ownership of its multiple sclerosis drug Tysabri to US partner Biogen Idec in return f(...)

  • « First
  • Prev
  • 9
  • 10
  • 11
  • 12